With mild injection-site reactions to a newly licensed biologic therapy, what is the recommended course of action?

With mild injection-site reactions to a newly licensed biologic therapy, what is the recommended course of action?

• A. No treatment is necessary; continue therapy
• B. Seek immediate emergency help
• C. Stop therapy temporarily
• D. Begin systemic immunosuppression

Answer: (A)

The main idea is that mild injection-site reactions to a biologic therapy are common and usually not harmful enough to stop treatment. When the reaction is only mild—such as slight redness, itching, or tenderness at the injection site—the best approach is to continue the biologic as prescribed. This maintains disease control and avoids unnecessary interruption of therapy. If the reaction remains mild, simple measures can help: apply a cool compress to the site, use a nonprescription topical agent for itching if needed, and ensure proper injection technique and site rotation to minimize irritation. Some patients also find short-term use of an oral antihistamine or a mild topical steroid helpful for itching, but these are optional and not required for all. Be alert for signs that would require changing course: increasing redness or swelling beyond a few centimeters, warmth, severe pain, fever, spreading rash, or any symptoms suggesting an systemic allergic reaction (such as trouble breathing, swelling of the face or tongue, or dizziness). In such cases, seek urgent medical evaluation. Stopping therapy or initiating systemic immunosuppression is not the appropriate response to mild local reactions, and emergency care is reserved for true life-threatening hypersensitivity events.

The main idea is that mild injection-site reactions to a biologic therapy are common and usually not harmful enough to stop treatment. When the reaction is only mild—such as slight redness, itching, or tenderness at the injection site—the best approach is to continue the biologic as prescribed. This maintains disease control and avoids unnecessary interruption of therapy.

If the reaction remains mild, simple measures can help: apply a cool compress to the site, use a nonprescription topical agent for itching if needed, and ensure proper injection technique and site rotation to minimize irritation. Some patients also find short-term use of an oral antihistamine or a mild topical steroid helpful for itching, but these are optional and not required for all.

Be alert for signs that would require changing course: increasing redness or swelling beyond a few centimeters, warmth, severe pain, fever, spreading rash, or any symptoms suggesting an systemic allergic reaction (such as trouble breathing, swelling of the face or tongue, or dizziness). In such cases, seek urgent medical evaluation. Stopping therapy or initiating systemic immunosuppression is not the appropriate response to mild local reactions, and emergency care is reserved for true life-threatening hypersensitivity events.